ArticleBritish journal of cancer2018

Everolimus and pazopanib (E/P) benefit genomically selected patients with metastatic urothelial carcinoma.

Joaquim Bellmunt et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.